Side-by-side · Research reference
CerebrolysinvsSemaglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED11/65 cited
BFDA-ApprovedFlagship15/53 cited
Cerebrolysin
Porcine Brain-Derived Peptide Mix · Phase 3
14–21 daysTreatment course
IV infusion · 100-250 mL saline · Daily
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Cerebrolysin
Semaglutide
Primary target
Multiple neurotrophic pathways — mimics BDNF, NGF, CNTF receptor activation
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Pathway
Cerebrolysin peptides → BDNF/NGF/CNTF receptor binding → TrkB/TrkA/LIFR signaling → neuroprotection, neuroplasticity, synaptogenesis
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Downstream effect
Reduced apoptosis (Bax ↓, Bcl-2 ↑), suppressed TNF-α inflammation, elevated endogenous BDNF, enhanced synaptic plasticity and motor recovery
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Feedback intact?
Yes — exogenous peptides do not suppress endogenous neurotrophic factor synthesis
Glucose-dependent insulin release preserves physiological feedback
Origin
Enzymatic breakdown of lipid-free porcine brain proteins → standardized low-MW peptide fraction (<10 kDa) + free amino acids
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Antibody development
Not reported in human trials; porcine origin theoretically immunogenic but no clinically significant allergic reactions documented
—
02Dosage Protocols
Parameter
Cerebrolysin
Semaglutide
Standard dose (stroke)
30–50 mL / day IVStaszewski 2026Afridi 2026
Most trials use 30 mL in 100-250 mL saline over 30-60 min.
—
Lower dose (dementia)
10–20 mL / day IV or IMKhatkova 2026
Chronic neurodegenerative conditions; intermittent courses.
—
Duration
10–21 days (acute); intermittent courses (chronic)
Stroke trials typically 10-14 days; rehabilitation phases may use repeated 10-day courses.
Indefinite for chronic indication
Discontinuation results in weight regain.
Timing (stroke)
Initiate within 12 hrs of symptom onset; up to 6 hrs optimal
Earlier initiation associated with better outcomes.
—
Adjunct to thrombectomy
30-50 mL daily × 10-14 days, starting day of EVT
Propensity-matched data show 12-mo mRS 0-2 improved from 35% to 49%.
—
Evidence basis
Phase 3 RCT + observational
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Administration route
IV infusion (preferred) or IM injection
IV allows higher doses; IM used in outpatient/chronic settings.
—
Standard dose (weight, Wegovy)
—
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
Frequency
—
Once weekly, same day each week
Titration schedule
—
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
Reconstitution
—
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Timing
—
Any time of day, with or without food
04Side Effects & Safety
Parameter
Cerebrolysin
Semaglutide
Injection site reaction
Mild pain, erythema (IM route)
Mild erythema, pruritus
Infusion reaction
Rare: flushing, transient hypotension during rapid IV
—
Agitation / Restlessness
Reported in <5% of patients; typically mild, self-limited
—
Serious adverse events
No significant increase vs placebo (RR 1.02, 95% CI 0.87-1.20)
—
Hemorrhagic transformation
Reduced incidence vs control (52% reduction in high-risk post-thrombolysis cohort)Kalinin 2025
—
Mortality
No increase; meta-analysis RR 0.89 (0.68-1.18)
—
Allergic reaction
Rare; porcine origin theoretically immunogenic but clinically insignificant
—
Seizure risk
Not elevated; safe in epilepsy populations
—
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Hypoglycemia
—
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Heart rate
—
Modest ↑ resting HR (~2-4 bpm)
Absolute Contraindications
Cerebrolysin
- ·Known hypersensitivity to porcine-derived products
- ·Active seizure disorder (relative — caution advised)
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Relative Contraindications
Cerebrolysin
- ·Severe renal impairment (amino acid load — monitor)
- ·Pregnancy / lactation (insufficient safety data)
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
05Administration Protocol
Parameter
Cerebrolysin
Semaglutide
1. Preparation (IV infusion)
Dilute prescribed dose (10-50 mL) in 100-250 mL 0.9% sodium chloride. Use immediately after preparation. Do not mix with other medications in same infusion bag.
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
2. Infusion rate
Administer over 30-60 minutes. Slower infusion reduces risk of transient hypotension or flushing. Monitor vital signs during first administration.
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
3. IM injection (alternative)
For 5-10 mL doses: inject deep IM into gluteal or deltoid muscle. Rotate sites if repeated daily. IM preferred for outpatient/chronic use.
Once weekly, same day. Day can be changed if ≥2 days separate doses.
4. Timing
Acute stroke: initiate within 6-12 hrs of symptom onset. Daily administration, preferably same time each day. Continue 10-21 days per protocol.
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
5. Storage
Store unopened ampoules at 15-25°C, protected from light. Do not freeze. Use diluted solution immediately; discard unused portion.
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
6. Co-administration
Compatible with standard stroke care (thrombolysis, thrombectomy, antiplatelet/anticoagulant therapy). Does not interfere with reperfusion therapies.
—
06Stack Synergy
Cerebrolysin
+ Semax
ModerateCerebrolysin (multimodal neurotrophic peptide mix) and Semax (ACTH(4-10) analogue) operate through complementary neuroprotective pathways. Cerebrolysin elevates BDNF and suppresses apoptosis/inflammation via TrkB/TrkA signaling, while Semax enhances neuroplasticity through BDNF upregulation and dopaminergic modulation. Combined use in stroke or TBI may amplify anti-apoptotic effects and accelerate cognitive/motor recovery, though no direct RCT data exist for the combination.
- Cerebrolysin
- 30 mL IV daily × 10-14 days
- Semax
- 300-600 mcg intranasal BID × 10-14 days
- Timing
- Concurrent during acute recovery phase
- Primary benefit
- Enhanced neuroprotection, accelerated motor/cognitive recovery post-stroke or TBI
+ BPC-157
Multi-pathwayCerebrolysin provides CNS-specific neurotrophic support (BDNF, NGF pathways), while BPC-157 offers systemic tissue repair via angiogenesis (VEGF upregulation) and anti-inflammatory effects. In traumatic brain injury or stroke, Cerebrolysin addresses neuronal survival and synaptic plasticity, whereas BPC-157 may enhance vascular repair and blood-brain barrier integrity. The combination targets both neuronal and vascular compartments of brain injury, though clinical validation is lacking.
- Cerebrolysin
- 30-50 mL IV daily × 14 days
- BPC-157
- 250-500 mcg SQ daily × 14-28 days
- Timing
- Initiate both within 24-48 hrs of injury
- Primary benefit
- Dual neuronal + vascular repair in TBI or stroke; accelerated functional recovery
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)